BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company ...

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

An anti-IL1RAP ADC was generated from an antibody selected from Cantargia's unique library of IL1RAP-targeting antibodies and conjugated to a tubulin-targeting payload using ImmunoGen (now part of ...

NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug ... where differentiation from tubulin and topoisomerase ...

The ADRX-0706 antibody is linked to a proprietary tubulin inhibitor payload, AP052, through Adcentrx's innovative i-Conjugation® technology platform – a core component in the design of the ...

Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing new ...

an older ADC that uses a tubulin inhibitor (antimitotic agent) DM1 as its payload. Third, Enhertu’s cysteine-based conjugation process is able to achieve a high drug-to-antibody ratio of around ...

The ADRX-0706 antibody is linked to a proprietary tubulin inhibitor payload, AP052, through Adcentrx's innovative i-Conjugation® technology using a cleavable linker and stable conjugation chemistry.

It was anti-tubulin payload. So ... I wonder if you could just update us on your – the confidence in your TIGIT antibody and any points of differentiation that you would cite for that molecule?